Detalhe da pesquisa
1.
Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7.
Lab Invest
; 104(4): 100321, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38154497
2.
Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study.
Cancers (Basel)
; 14(2)2022 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35053582
3.
Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.
Clin Cancer Res
; 23(14): 3794-3801, 2017 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28159814
4.
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
J Clin Oncol
; 29(2): 242-8, 2011 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-21115872
5.
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
J Clin Oncol
; 24(7): 1127-35, 2006 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16505432